第三條 本細則所稱董事是指要本公司支取薪酬的董事，高級管理人員是指 公司的總經理、副總經理、董事會秘書、財務總監以及由董事會明確聘任為公司 高級管理人員的其他人員。本細則所稱「總經理」即《公司法》所稱「經理」。 第二章 人員組成 第四條 薪酬委員會由三名或以上的董事組成，成員應當為單數，獨立非執 行董事佔二分之一以上。 第五條 薪酬委員會委員由董事長或董事會提名委員會提名，並由董事會以 全體董事過半數選舉產生。選舉委員的提案獲得通過後，新任委員在董事會會議 結束後立即就任。 深圳市精鋒醫療科技股份有限公司 董事會薪酬委員會工作細則 第一章 總則 第一條 為進一步建立健全深圳市精鋒醫療科技股份有限公司（以下簡稱「公 司」）薪酬與考核管理制度，完善公司治理結構，根據《中華人民共和國公司法》 （以下簡稱「《公司法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱 「《上市規則》」）、《上市規則》附錄C1所載的《企業管治守則》等相關法律、法規、 規範性文件及H股發行後適用的《深圳市精鋒醫療科技股份有限公司章程》（以下 簡稱「《公司章程》」），依照董事會決議，公司特設立董事會（「董事會」）薪酬委員 會，並結合公司 ...

第一章 總則 第一條 為強化深圳市精鋒醫療科技股份有限公司（以下簡稱「公司」）董事會 （「董事會」）決策功能，持續完善公司內部控制體系建設，確保董事會的有效監督 管理，不斷完善公司治理結構，根據《中華人民共和國公司法》（以下簡稱「《公司 法》」）、《香港聯合交易所有限公司證券上市規則》（以下簡稱「《上市規則》」）、《上 市規則》附錄C1所載的《企業管治守則》、香港會計師公會《審核委員會有效運作 指引》等相關法律、法規、規範性文件及H股發行後適用的《深圳市精鋒醫療科技 股份有限公司章程》（以下簡稱「《公司章程》」），依照董事會決議，公司特設立董 事會審計委員會，並結合公司實際，制定本《深圳市精鋒醫療科技股份有限公司 董事會審計委員會工作細則》（以下簡稱「本細則」）。 第二條 董事會審計委員會是公司董事會下設的專門工作機構，主要職能是 檢討公司財務狀況、審閱公司的財務資料、就財務信息的真實性、完整性和準確 性作出判斷、檢查內部監控制度的執行和效果，並主要負責公司與外部審計的溝 通及對其的監督核查、對內部審計的監管、公司內部控制體系的評價與完善，並 對此提出建議，以及對公司正在運作的重大投資項目等進行風險評估。董事 ...

第一條 為維護深圳市精鋒醫療科技股份有限公司（以下簡稱「公司」）、股 東、職工和債權人的合法權益，規範公司的組織和行為，根據《中華人民共和國 公司法》（以下簡稱「《公司法》」）《中華人民共和國證券法》《境內企業境外發行證 券和上市管理試行辦法》《上市公司章程指引》《香港聯合交易所有限公司證券上 市規則》（以下簡稱「《香港上市規則》」）和其他法律、法規、部門規章、規範性文 件及公司股票上市地證券監督管理機構的有關規定，結合公司實際情況，制定本 章程。 第二條 公司系依照《公司法》及其他有關規定成立的股份有限公司。 公司是在深圳市精鋒醫療科技有限公司的基礎上，以發起方式依法整體變更 設立；在深圳市市場監督管理局註冊登記，取得公司營業執照，統一社會信用代 碼為91440300MA5EH2LU6N。 深圳市精鋒醫療科技股份有限公司 章程 | 第一章 | 總則 | 1 | | --- | --- | --- | | 第二章 | 經營宗旨和範圍 | 2 | | 第三章 | 股份 | 3 | | 第一節 | 股份發行 | 3 | | 第二節 | 股份增減和回購 | 7 | | 第三節 | 股份轉讓 | 8 | | 第四章 ...

Group 1 - The core offering of the company includes advanced surgical robots designed for minimally invasive procedures, with a focus on market potential in the surgical robotics sector [1][2] - The company plans to issue 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise approximately HKD 1.2 billion, with a public offering accounting for 10% of the total shares [1] - The company has received significant interest, with a reported oversubscription of 398 times the public offering amount, indicating strong demand for its shares [1] Group 2 - The product lineup includes the Precision® Multi-Port Surgical Robot and the Precision® Single-Port Surgical Robot, both of which are designed for various surgical applications across urology, gynecology, and general surgery [2] - The company has secured cornerstone investment agreements totaling USD 75 million from notable investors, including Tencent and OrbiMed Genesis, which will support the share issuance [2] - The net proceeds from the global offering are expected to be approximately HKD 1.1166 billion, with allocations planned for R&D, commercialization, capacity expansion, and potential strategic acquisitions [3]

Group 1 - The company, 精锋医疗-B (02675), plans to conduct an IPO from December 30, 2025, to January 5, 2026, issuing 27.72 million H-shares at a price of HKD 43.24 per share, aiming to raise nearly HKD 1.2 billion [1] - The company is an advanced surgical robotics firm in the medical device industry, focusing on the design, development, and manufacturing of surgical robots, with products in various stages of research and development [1][2] - The company has received significant interest in its IPO, with a reported margin loan of HKD 478.7 billion and an oversubscription rate of 398 times for the public offering [1] Group 2 - The product portfolio includes two core self-developed products: the 精锋多孔腔镜手术机器人 (multi-port laparoscopic surgical robot) and the 精锋单孔腔镜手术机器人 (single-port laparoscopic surgical robot), along with a non-core product, the 精锋支气管镜机器人 (bronchoscopic robot) [2] - The company has established cornerstone investment agreements with several investors, including OrbiMed Genesis and Tencent, agreeing to subscribe for a total of USD 75 million worth of shares under certain conditions [2] - The net proceeds from the global offering are estimated to be approximately HKD 1.1166 billion, with allocations planned for R&D (42%), commercialization (20%), capacity expansion (10%), other products (8%), strategic acquisitions (10%), and working capital (10%) [3]

Core Viewpoint - Precision Medicine is set to debut on the Hong Kong Stock Exchange, aiming to raise approximately HKD 1.199 billion through the issuance of 27.7222 million shares at a price of HKD 43.24 per share, with trading expected to commence on January 8, 2026 [2][10]. Financial Performance - For the first half of 2025, Precision Medicine reported revenue of RMB 149 million and a gross profit of RMB 93.85 million [2][10]. Investment Background - Chengdu Mingsheng Investment Co., Ltd. invested RMB 5 million during the angel round, which has appreciated to RMB 675 million, yielding a remarkable return of 135 times over eight years [2][10]. - The company was founded in May 2017 and received its first investment four months later [3][10]. Shareholding Structure - As of the IPO, Chengdu Mingsheng holds 17.50464 million shares, representing 4.86% of the total shares, making it the fourth-largest shareholder [7][15]. - The major shareholders include Dr. Wang with 29.05% and Dr. Gao with 14.35% of the shares [15]. Future Prospects - The shares held by Chengdu Mingsheng are subject to a 12-month lock-up period post-IPO, with a market value of approximately HKD 757 million, equivalent to RMB 680 million [15].

Group 1 - The company plans to globally offer 27.72 million shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, along with an over-allotment option of 4.16 million shares [1] - The subscription period for the shares is set from December 30, 2025, to January 5, 2026, with a maximum offer price of HKD 43.24 per share and an entry fee of approximately HKD 4,367.61 for a board lot of 100 shares [1] - The total expected fundraising amount is HKD 1.199 billion, with a net amount of HKD 1.117 billion, which will be allocated for ongoing and planned R&D of core products, commercialization of core products, working capital, capacity expansion, potential strategic acquisitions or investments in the surgical robotics industry, and other products under development [1] Group 2 - The company is expected to be listed on the main board on January 8, 2026, with Morgan Stanley Asia Limited and GF Securities (Hong Kong) Limited acting as joint sponsors [2] - The company's main business includes economic information consulting, software development, import and export of electronic devices and medical equipment, and R&D, production, and sales of smart devices, medical robots, and related equipment [2] - The company's net profits for the fiscal years 2023, 2024, and the first half of 2025 (ending June 30) are projected to be -213 million, -219 million, and -89.09 million respectively [2]

Group 1 - The company plans to globally offer 27.72 million shares, with 2.77 million shares available in Hong Kong and 24.95 million shares for international offering, along with an over-allotment option of 4.16 million shares [1] - The subscription period for the shares is set from December 30, 2025, to January 5, 2026, with a maximum offer price of HKD 43.24 per share and an entry fee of approximately HKD 4,367.61 [1] - The total expected fundraising amount is HKD 1.199 billion, with a net amount of HKD 1.117 billion, which will be allocated for ongoing and planned R&D of core products, commercialization of core products, working capital, capacity expansion, potential strategic acquisitions or investments in the surgical robotics industry, and other products under development [1] Group 2 - The company is expected to be listed on the main board on January 8, 2026, with Morgan Stanley Asia Limited and GF Securities (Hong Kong) Limited acting as joint sponsors [2] - The company's main business includes economic information consulting, software development, import and export of electronic devices and medical equipment, R&D, production, and sales of smart devices, medical robots, and related services [2] - The company reported net losses of HKD 213 million, HKD 219 million, and HKD 89.09 million for the fiscal years 2023, 2024, and the first half of 2025, respectively [2]

深圳市精鋒醫療科技股份有限公司 Shenzhen Edge Medical Co., Ltd. 股份代號 : 2675 （於中華人民共和國註冊成立的股份有限公司） 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 重要提示： 閣下如對本文件的任何內容有任何疑問，應尋求獨立專業意見。 Shenzhen Edge Medical Co., Ltd. 深圳市精鋒醫療科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） 全球發售 | 全球發售項下的發售股份數目 | ： | 27,722,200股H股（視乎超額配股權行使 | | --- | --- | --- | | 與否而定） | | | | 香港發售股份數目 | ： | 2,772,300股H股（可予重新分配） | | 國際發售股份數目 | ： | 24,949,900股H股（可予重新分配及視乎 | | 超額配股權行使與否而定） | | | | 發售價 | ： | 每股H股43.24港元，另加1.0%經紀 | ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任。 除本公告另有界定者外，本公告所用詞彙與深圳市精鋒醫療科技股份有限公司（「本公司」）日期 為2025年12月30日的香港招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 有意投資者於決定是否投資於發售股份前，務請細閱招股章程中有關下文所述全球發售的詳細 資料。任何有關發售股份的投資決定應僅依據招股章程所提供的資料作出。 本公告不得直接或間接於或向美國境內（包括其領土及屬地、美國任何州及哥倫比亞特區）發 佈、刊發、分發。本公告並不構成或組成於美國或任何其他司法管轄區購買或認購證券的任 何要約或招攬的一部分。本公告所述證券並無亦不會根據《1933年美國證券法》（經不時修訂） （「《美國證券法》」）或美國任何州或其他司法管轄區的證券法登記。除非進行獲豁免遵守《美國 證券法》的登記 ...